Brainomix Presents Robust Validation of Its FDA-Cleared e-Lung Technology from its Collaboration with Boehringer Ingelheim
The Californer/10314007

Trending...
OXFORD, England and CHICAGO, May 16, 2025 ~ Brainomix, a leading company in AI-powered imaging solutions for lung fibrosis and stroke, will be presenting new evidence at the upcoming American Thoracic Society (ATS) Conference in San Francisco. The evidence will validate the effectiveness of their Brainomix 360 e-Lung technology in accurately and sensitively identifying progressive pulmonary fibrosis.

The validation comes as a result of a research collaboration between Brainomix and Boehringer Ingelheim, a global leader in pulmonary fibrosis therapies. Through this collaboration, Brainomix was granted access to the landmark INBUILD clinical trial dataset to conduct the first quantitative CT analysis. The results have firmly established e-Lung as a reliable tool for identifying progressive pulmonary fibrosis and its prognostic accuracy in predicting patients at risk.

Dr Susanne Stowasser, Associate Head of Medicine Therapeutic Area Inflammation at Boehringer Ingelheim, expressed their commitment to creating value for patients through collaborations. She stated that the imaging data presented at ATS from their INBUILD clinical trial is part of their collaboration with Brainomix and others to advance the development of imaging biomarkers for better prognostication and prediction of response to therapy.

More on The Californer
The studies will be presented on May 21st at ATS by Prof Anand Devaraj and Dr Peter George from the Royal Brompton Hospital in London. They will showcase Brainomix 360 e-Lung, an imaging software powered by novel proprietary technology that automatically quantifies CT biomarkers in patients with interstitial lung disease (ILD). With its recent expansion of FDA clearance, the next generation e-Lung technology represents a significant step forward in improving care for ILD patients with improved AI and machine learning algorithms.

Pulmonary fibrosis is a chronic lung condition that is progressive and life-limiting. Without treatment, patients can have a lifespan as short as three to five years from diagnosis. However, due to challenges in identifying the disease, patients often wait up to two years for a diagnosis. Early initiation of treatment is crucial for the best outcome and survival, but identifying eligible patients based on imaging can be difficult, even for experts.

Dr Peter George, Consultant Pulmonologist at the Royal Brompton NHS Trust UK and Brainomix Medical Director, emphasized the power of e-Lung in accurately identifying progression and its prognostic capabilities. He stated that this ability to track results across multiple scan timepoints can help physicians make better treatment decisions earlier on. The prognostic capabilities also allow physicians to prioritize at-risk patients for earlier follow-up and escalate their care in a timely manner.

More on The Californer
The strategic partnership between Brainomix and Boehringer Ingelheim, announced in 2024, aims to improve the care of patients with progressive pulmonary fibrosis. Early collaborations with leading US pulmonary sites and registries have already provided real-world validation of e-Lung in improving the identification of patients with progressive pulmonary fibrosis.

Brainomix will be exhibiting at ATS (booth #1563) and will have a series of key scientific sessions. The "Imaging-Based Advances in Fibrotic ILD" symposium will take place on Wednesday, May 21 from 11am – 1pm in Rooms 3014-3018, West Building of the Moscone Center. Three (3) Brainomix studies will be presented by Dr Peter George and Prof Anand Devaraj:

- e-Lung Biomarkers Are Associated With Future Progressive Pulmonary Fibrosis Independent of UIP Status on CT

- Baseline Quantitative CT Predicts Rate of Decline in Forced Vital Capacity and Clinically Relevant Outcomes in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial

- Effect of Nintedanib on Quantitative CT in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial

In conclusion, Brainomix's innovative e-Lung technology, validated by their collaboration with Boehringer Ingelheim, has the potential to significantly improve the care and outcomes of patients with progressive pulmonary fibrosis. Their studies and presentations at ATS will provide valuable insights and advancements in the field of ILD imaging.
Filed Under: Business
Show All News | Disclaimer | Report Violation

0 Comments

Latest on The Californer